Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer

A marker of poor prognosis in HER2/neu-overexpressing breast cancer patients

Xiangshan Zhao, Sameer Mirza, Alaa Alshareeda, Ying Zhang, Channabasavaiah B Gurumurthy, Aditya Bele, Jun Hyun Kim, Shakur Mohibi, Monica Goswami, Subodh M Lele, William West, Fang Qiu, Ian O. Ellis, Emad A. Rakha, Andrew R. Green, Hamid Band, Vimla Band

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Uncontrolled proliferation is one of the hallmarks of breast cancer. We have previously identified the human Ecd protein (human ortholog of Drosophila Ecdysoneless, hereafter called Ecd) as a novel promoter of mammalian cell cycle progression, a function related to its ability to remove the repressive effects of Rb-family tumor suppressors on E2F transcription factors. Given the frequent dysregulation of cell cycle regulatory components in human cancer, we used immunohistochemistry of paraffin-embedded tissues to examine Ecd expression in normal breast tissue versus tissues representing increasing breast cancer progression. Initial studies of a smaller cohort without outcomes information showed that Ecd expression was barely detectable in normal breast tissue and in hyperplasia of breast, but high levels of Ecd were detected in benign breast hyperplasia, ductal carcinoma in situ (DCIS) and infiltrating ductal carcinoma (IDCs) of the breast. In this cohort of 104 IDC patients, Ecd expression levels showed a positive correlation with higher grade (P = 0.04). Further analyses of Ecd expression using a larger, independent cohort (954) confirmed these results, with a strong positive correlation of elevated Ecd expression with higher histological grade (P = 0.013), mitotic index (P = 0.032), and Nottingham Prognostic Index score (P = 0.014). Ecd expression was positively associated with HER2/neu (P = 0.002) overexpression, a known marker of poor prognosis in breast cancer. Significantly, increased Ecd expression showed a strong positive association with shorter breast cancer specific survival (BCSS) (P = 0.008) and disease-free survival (DFS) (P = 0.003) in HER2/neu overexpressing patients. Taken together, our results reveal Ecd as a novel marker for breast cancer progression and show that levels of Ecd expression predict poorer survival in Her2/neu overexpressing breast cancer patients.

Original languageEnglish (US)
Pages (from-to)171-180
Number of pages10
JournalBreast Cancer Research and Treatment
Volume134
Issue number1
DOIs
StatePublished - Jul 1 2012

Fingerprint

Cell Cycle
Breast Neoplasms
Breast
Hyperplasia
E2F Transcription Factors
Carcinoma, Ductal, Breast
Ductal Carcinoma
Mitotic Index
Aptitude
Carcinoma, Intraductal, Noninfiltrating
Survival
Paraffin
Drosophila
Disease-Free Survival
Neoplasms
Immunohistochemistry
Proteins

Keywords

  • Breast cancer
  • Cell cycle
  • DCIS
  • Ecdysoneless
  • HER2/neu
  • IDC

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer : A marker of poor prognosis in HER2/neu-overexpressing breast cancer patients. / Zhao, Xiangshan; Mirza, Sameer; Alshareeda, Alaa; Zhang, Ying; Gurumurthy, Channabasavaiah B; Bele, Aditya; Kim, Jun Hyun; Mohibi, Shakur; Goswami, Monica; Lele, Subodh M; West, William; Qiu, Fang; Ellis, Ian O.; Rakha, Emad A.; Green, Andrew R.; Band, Hamid; Band, Vimla.

In: Breast Cancer Research and Treatment, Vol. 134, No. 1, 01.07.2012, p. 171-180.

Research output: Contribution to journalArticle

Zhao, Xiangshan ; Mirza, Sameer ; Alshareeda, Alaa ; Zhang, Ying ; Gurumurthy, Channabasavaiah B ; Bele, Aditya ; Kim, Jun Hyun ; Mohibi, Shakur ; Goswami, Monica ; Lele, Subodh M ; West, William ; Qiu, Fang ; Ellis, Ian O. ; Rakha, Emad A. ; Green, Andrew R. ; Band, Hamid ; Band, Vimla. / Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer : A marker of poor prognosis in HER2/neu-overexpressing breast cancer patients. In: Breast Cancer Research and Treatment. 2012 ; Vol. 134, No. 1. pp. 171-180.
@article{ab9a446936614e84b0491af4a07297b6,
title = "Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: A marker of poor prognosis in HER2/neu-overexpressing breast cancer patients",
abstract = "Uncontrolled proliferation is one of the hallmarks of breast cancer. We have previously identified the human Ecd protein (human ortholog of Drosophila Ecdysoneless, hereafter called Ecd) as a novel promoter of mammalian cell cycle progression, a function related to its ability to remove the repressive effects of Rb-family tumor suppressors on E2F transcription factors. Given the frequent dysregulation of cell cycle regulatory components in human cancer, we used immunohistochemistry of paraffin-embedded tissues to examine Ecd expression in normal breast tissue versus tissues representing increasing breast cancer progression. Initial studies of a smaller cohort without outcomes information showed that Ecd expression was barely detectable in normal breast tissue and in hyperplasia of breast, but high levels of Ecd were detected in benign breast hyperplasia, ductal carcinoma in situ (DCIS) and infiltrating ductal carcinoma (IDCs) of the breast. In this cohort of 104 IDC patients, Ecd expression levels showed a positive correlation with higher grade (P = 0.04). Further analyses of Ecd expression using a larger, independent cohort (954) confirmed these results, with a strong positive correlation of elevated Ecd expression with higher histological grade (P = 0.013), mitotic index (P = 0.032), and Nottingham Prognostic Index score (P = 0.014). Ecd expression was positively associated with HER2/neu (P = 0.002) overexpression, a known marker of poor prognosis in breast cancer. Significantly, increased Ecd expression showed a strong positive association with shorter breast cancer specific survival (BCSS) (P = 0.008) and disease-free survival (DFS) (P = 0.003) in HER2/neu overexpressing patients. Taken together, our results reveal Ecd as a novel marker for breast cancer progression and show that levels of Ecd expression predict poorer survival in Her2/neu overexpressing breast cancer patients.",
keywords = "Breast cancer, Cell cycle, DCIS, Ecdysoneless, HER2/neu, IDC",
author = "Xiangshan Zhao and Sameer Mirza and Alaa Alshareeda and Ying Zhang and Gurumurthy, {Channabasavaiah B} and Aditya Bele and Kim, {Jun Hyun} and Shakur Mohibi and Monica Goswami and Lele, {Subodh M} and William West and Fang Qiu and Ellis, {Ian O.} and Rakha, {Emad A.} and Green, {Andrew R.} and Hamid Band and Vimla Band",
year = "2012",
month = "7",
day = "1",
doi = "10.1007/s10549-011-1946-8",
language = "English (US)",
volume = "134",
pages = "171--180",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer

T2 - A marker of poor prognosis in HER2/neu-overexpressing breast cancer patients

AU - Zhao, Xiangshan

AU - Mirza, Sameer

AU - Alshareeda, Alaa

AU - Zhang, Ying

AU - Gurumurthy, Channabasavaiah B

AU - Bele, Aditya

AU - Kim, Jun Hyun

AU - Mohibi, Shakur

AU - Goswami, Monica

AU - Lele, Subodh M

AU - West, William

AU - Qiu, Fang

AU - Ellis, Ian O.

AU - Rakha, Emad A.

AU - Green, Andrew R.

AU - Band, Hamid

AU - Band, Vimla

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Uncontrolled proliferation is one of the hallmarks of breast cancer. We have previously identified the human Ecd protein (human ortholog of Drosophila Ecdysoneless, hereafter called Ecd) as a novel promoter of mammalian cell cycle progression, a function related to its ability to remove the repressive effects of Rb-family tumor suppressors on E2F transcription factors. Given the frequent dysregulation of cell cycle regulatory components in human cancer, we used immunohistochemistry of paraffin-embedded tissues to examine Ecd expression in normal breast tissue versus tissues representing increasing breast cancer progression. Initial studies of a smaller cohort without outcomes information showed that Ecd expression was barely detectable in normal breast tissue and in hyperplasia of breast, but high levels of Ecd were detected in benign breast hyperplasia, ductal carcinoma in situ (DCIS) and infiltrating ductal carcinoma (IDCs) of the breast. In this cohort of 104 IDC patients, Ecd expression levels showed a positive correlation with higher grade (P = 0.04). Further analyses of Ecd expression using a larger, independent cohort (954) confirmed these results, with a strong positive correlation of elevated Ecd expression with higher histological grade (P = 0.013), mitotic index (P = 0.032), and Nottingham Prognostic Index score (P = 0.014). Ecd expression was positively associated with HER2/neu (P = 0.002) overexpression, a known marker of poor prognosis in breast cancer. Significantly, increased Ecd expression showed a strong positive association with shorter breast cancer specific survival (BCSS) (P = 0.008) and disease-free survival (DFS) (P = 0.003) in HER2/neu overexpressing patients. Taken together, our results reveal Ecd as a novel marker for breast cancer progression and show that levels of Ecd expression predict poorer survival in Her2/neu overexpressing breast cancer patients.

AB - Uncontrolled proliferation is one of the hallmarks of breast cancer. We have previously identified the human Ecd protein (human ortholog of Drosophila Ecdysoneless, hereafter called Ecd) as a novel promoter of mammalian cell cycle progression, a function related to its ability to remove the repressive effects of Rb-family tumor suppressors on E2F transcription factors. Given the frequent dysregulation of cell cycle regulatory components in human cancer, we used immunohistochemistry of paraffin-embedded tissues to examine Ecd expression in normal breast tissue versus tissues representing increasing breast cancer progression. Initial studies of a smaller cohort without outcomes information showed that Ecd expression was barely detectable in normal breast tissue and in hyperplasia of breast, but high levels of Ecd were detected in benign breast hyperplasia, ductal carcinoma in situ (DCIS) and infiltrating ductal carcinoma (IDCs) of the breast. In this cohort of 104 IDC patients, Ecd expression levels showed a positive correlation with higher grade (P = 0.04). Further analyses of Ecd expression using a larger, independent cohort (954) confirmed these results, with a strong positive correlation of elevated Ecd expression with higher histological grade (P = 0.013), mitotic index (P = 0.032), and Nottingham Prognostic Index score (P = 0.014). Ecd expression was positively associated with HER2/neu (P = 0.002) overexpression, a known marker of poor prognosis in breast cancer. Significantly, increased Ecd expression showed a strong positive association with shorter breast cancer specific survival (BCSS) (P = 0.008) and disease-free survival (DFS) (P = 0.003) in HER2/neu overexpressing patients. Taken together, our results reveal Ecd as a novel marker for breast cancer progression and show that levels of Ecd expression predict poorer survival in Her2/neu overexpressing breast cancer patients.

KW - Breast cancer

KW - Cell cycle

KW - DCIS

KW - Ecdysoneless

KW - HER2/neu

KW - IDC

UR - http://www.scopus.com/inward/record.url?scp=84863925514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863925514&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1946-8

DO - 10.1007/s10549-011-1946-8

M3 - Article

VL - 134

SP - 171

EP - 180

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -